🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is — my results so far Page 3

Can we talk about how SLOW the FDA is — my results so far

NurseAsh_DET Tue, Nov 18, 2025 at 7:47 PM 43 replies 1,294 viewsPage 3 of 9
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Nov 21, 2025 at 3:36 PM#11
hyun_seoul said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

hyun_seoul has the substance of this right. The condition it depends on is worth stating. Yes, and the corollary is less popular: if the reasoning holds, it also holds where it produces an answer we do not like.

50 23FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 47 others
Reply Quote Save Share Report
KetoKyle
Member
678
3,456
Jul 2024
Utah
Nov 23, 2025 at 5:57 AM#12
newstart_MO said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Saving this. It is the first explanation that did not require me to already understand it. Sending this to two other people who asked me the same thing last week.

1 24JenMemphis
Reply Quote Save Share Report
NauseaFreeNow
Member
345
1,234
Aug 2024
Indiana
Nov 24, 2025 at 8:16 PM#13
hyun_seoul said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

Pushing back on hyun_seoul here. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.

2 0Dr.PulmRoch, maya_sedona
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Nov 26, 2025 at 10:34 AM#14

One concrete data point for the thread. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

3 1DebRD_ATL, KristenIndy, MarkLI_maint
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Nov 28, 2025 at 12:52 AM#15

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Carry on.

4 2PurityPaulOR, MaxMetOK, MounjBrad and 1 other
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register